Vyne Therapeutics Valuation
| VYNE Stock | USD 1.72 0.04 2.38% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Vyne Therapeutics has a current Real Value of $1.61 per share. The regular price of the company is $1.72. Our model measures the value of Vyne Therapeutics from inspecting the company fundamentals such as Shares Owned By Insiders of 8.31 %, current valuation of (34.5 M), and Return On Equity of -0.6 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Vyne Therapeutics' valuation include:
Price Book 0.5169 | Enterprise Value | Enterprise Value Ebitda 1.8403 | Price Sales 51.0033 | Trailing PE 1.7442 |
Overvalued
Today
Please note that Vyne Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Vyne Therapeutics is based on 3 months time horizon. Increasing Vyne Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Vyne stock is determined by what a typical buyer is willing to pay for full or partial control of Vyne Therapeutics. Since Vyne Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vyne Stock. However, Vyne Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.72 | Real 1.61 | Target 5.58 | Hype 1.68 | Naive 1.82 |
The real value of Vyne Stock, also known as its intrinsic value, is the underlying worth of Vyne Therapeutics Company, which is reflected in its stock price. It is based on Vyne Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Vyne Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Vyne Therapeutics helps investors to forecast how Vyne stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vyne Therapeutics more accurately as focusing exclusively on Vyne Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Vyne Therapeutics' intrinsic value based on its ongoing forecasts of Vyne Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Vyne Therapeutics' closest peers. If more than one evaluation category is relevant for Vyne Therapeutics we suggest using both methods to arrive at a better estimate.
Vyne Therapeutics Cash |
|
Vyne Valuation Trend
Comparing Vyne Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Vyne Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Vyne Therapeutics Total Value Analysis
Vyne Therapeutics is at this time estimated to have valuation of (34.5 M) with market capitalization of 44.25 M, debt of 99 K, and cash on hands of 42.81 M. The negative valuation of Vyne Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Vyne Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(34.5 M) | 44.25 M | 99 K | 42.81 M |
Vyne Therapeutics Investor Information
About 56.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.52. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vyne Therapeutics had not issued any dividends in recent years. The entity had 1:18 split on the 13th of February 2023. Based on the key indicators related to Vyne Therapeutics' liquidity, profitability, solvency, and operating efficiency, Vyne Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Vyne Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vyne Therapeutics has an asset utilization ratio of 0.75 percent. This indicates that the Company is making $0.007488 for each dollar of assets. An increasing asset utilization means that Vyne Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Vyne Therapeutics Ownership Allocation
The market capitalization of Vyne Therapeutics is $44.25 Million. Over half of Vyne Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Vyne Therapeutics Profitability Analysis
The company reported the previous year's revenue of 501 K. Net Loss for the year was (39.83 M) with profit before overhead, payroll, taxes, and interest of 477 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Vyne Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Vyne Therapeutics and how it compares across the competition.
About Vyne Therapeutics Valuation
The stock valuation mechanism determines Vyne Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Vyne Therapeutics. We calculate exposure to Vyne Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vyne Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 501 K | 475.9 K | |
| Pretax Profit Margin | (79.45) | (83.42) | |
| Operating Profit Margin | (87.10) | (91.45) | |
| Net Loss | (79.51) | (83.48) | |
| Gross Profit Margin | 0.70 | 0.51 |
Vyne Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Vyne Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 42.6 M |
Vyne Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Vyne Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Vyne we look at many different elements of the entity such as Vyne's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Vyne Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Vyne Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Vyne Therapeutics' worth.Complementary Tools for Vyne Stock analysis
When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |